Novo Holdings A/S 4
4 · Hemab Therapeutics Holdings, Inc. · Filed May 6, 2026
Research Summary
AI-generated summary of this filing
Hemab (COAG) 10% Owner Novo Holdings Converts Preferred into 4.18M Shares
What Happened
Novo Holdings A/S, listed as a 10% owner of Hemab Therapeutics Holdings, Inc. (COAG), reported conversions of derivative securities into common stock on May 4, 2026. The filing shows an acquisition entry of 4,180,550 common shares (conversion of derivative security, Code C). The filing also lists conversions recorded as dispositions of 23,343; 71,866; 62,121; and 32,695 shares (all $0.00, derivative conversions). Per the filing footnote, these reflect automatic conversions of preferred shares into common stock in connection with the issuer's IPO.
Key Details
- Transaction date: May 4, 2026. Form filed: May 6, 2026 (filed within the typical two-business-day Form 4 window).
- Primary entry: 4,180,550 common shares acquired via conversion (derivative conversion, Code C).
- Additional conversions recorded as disposals: 23,343; 71,866; 62,121; and 32,695 shares (all $0.00). Total of those disposals: 190,025 shares.
- Price: conversions were for no additional consideration (recorded as $0.00 / N/A).
- Footnote F1: Series Seed, A, B and C preferred automatically converted into common immediately prior to the IPO on a 22-for-1 basis, had no expiration, and required no payment.
- Shares owned after the transaction: not specified in the provided excerpt of the filing.
- Insider type: institutional 10% owner (Novo Holdings A/S), not an executive—these are structural conversions, not open-market trades.
Context
These entries reflect automatic pre-IPO conversions of preferred stock into common stock, not purchases or market sales. For retail investors, such conversions are procedural (capital structure changes around an IPO) and do not by themselves indicate insider buying or selling sentiment. Subsequent open-market trades by the holder would be more informative about their view of the company.
Insider Transaction Report
- Conversion
Common Stock
[F1]2026-05-04+4,180,550→ 4,180,550 total - Conversion
Series Seed Preferred Stock
[F1]2026-05-04−23,343→ 0 total→ Common Stock (513,546 underlying) - Conversion
Series A Preferred Stock
[F1]2026-05-04−71,866→ 0 total→ Common Stock (1,581,052 underlying) - Conversion
Series B Preferred Stock
[F1]2026-05-04−62,121→ 0 total→ Common Stock (1,366,662 underlying) - Conversion
Series C Preferred Stock
[F1]2026-05-04−32,695→ 0 total→ Common Stock (719,290 underlying)
Footnotes (1)
- [F1]Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.